• 1. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

Recent Advances in the Study of 2-fluoro-5-(4-methoxy-3-methylphenyl)benzoic Acid (CAS: 1184537-99-2)

The compound 2-fluoro-5-(4-methoxy-3-methylphenyl)benzoic Acid (CAS: 1184537-99-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and mechanisms of action, providing valuable insights for drug development.

One of the key areas of research has been the optimization of synthetic routes for 2-fluoro-5-(4-methoxy-3-methylphenyl)benzoic Acid. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an efficient multi-step synthesis protocol that improved yield and purity. The protocol involved the use of palladium-catalyzed cross-coupling reactions, followed by selective fluorination and carboxylation steps. This advancement is critical for scaling up production for preclinical and clinical studies.

Pharmacological evaluations have revealed that 2-fluoro-5-(4-methoxy-3-methylphenyl)benzoic Acid exhibits potent anti-inflammatory and analgesic properties. In vitro studies using human cell lines indicated that the compound inhibits cyclooxygenase-2 (COX-2) activity with high selectivity, suggesting its potential as a next-generation non-steroidal anti-inflammatory drug (NSAID). Furthermore, in vivo studies in rodent models confirmed its efficacy in reducing inflammation and pain with minimal gastrointestinal side effects, a common limitation of traditional NSAIDs.

Another groundbreaking study explored the compound's role in oncology. Researchers found that 2-fluoro-5-(4-methoxy-3-methylphenyl)benzoic Acid acts as a modulator of the tumor microenvironment by inhibiting specific signaling pathways involved in angiogenesis and metastasis. These findings, published in Cancer Research (2024), highlight the compound's dual functionality as both an anti-inflammatory and anti-cancer agent, opening new avenues for combination therapies.

Despite these promising results, challenges remain in the clinical translation of 2-fluoro-5-(4-methoxy-3-methylphenyl)benzoic Acid. Pharmacokinetic studies have identified issues related to bioavailability and metabolic stability, which are currently being addressed through structural modifications and formulation strategies. Collaborative efforts between academic institutions and pharmaceutical companies are underway to overcome these hurdles and accelerate the compound's progression to clinical trials.

In conclusion, 2-fluoro-5-(4-methoxy-3-methylphenyl)benzoic Acid (CAS: 1184537-99-2) represents a versatile and promising candidate in the field of medicinal chemistry. Its multifaceted pharmacological profile, combined with recent advancements in synthesis and mechanistic understanding, positions it as a valuable asset for future drug development. Continued research and collaboration will be essential to fully realize its therapeutic potential.

• 1179609-46-1(2-fluoro-4-(2-methoxyphenyl)benzoic Acid)
• 1179926-83-0(2-fluoro-5-(5-fluoro-2-methoxyphenyl)benzoic Acid)
• 1179916-77-8(4-(2,4-Dimethoxyphenyl)-2-fluorobenzoic acid)
• 1183866-69-4(2-Fluoro-5-(4-methoxyphenyl)benzoic acid)
• 1183759-96-7(2-Fluoro-4-(4-methoxyphenyl)benzoic acid)
• 1183080-90-1(2-fluoro-4-(4-methoxy-3-methylphenyl)benzoic Acid)
• 1178303-59-7(2-fluoro-5-(2-methoxyphenyl)benzoic acid)
• 1261992-71-5(2-fluoro-5-(2-methoxy-5-methylphenyl)benzoic Acid)
• 1184619-67-7(2-Fluoro-5-(3-methoxyphenyl)benzoic acid)
• 877383-80-7(2-fluoro-4-(5-fluoro-2-methoxyphenyl)benzoic Acid)